{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-23-000094","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.182185+00:00","generated_at":"2026-06-15T05:55:42.411515+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CareDx Q1 revenue $77.3M (-3% YoY); withdraws 2023 guidance on billing article uncertainty","bullets":["Record test volumes 49,900 (AlloMap/AlloSure), up 17% YoY; testing services revenue $61.8M.","GAAP net loss $23.7M ($0.44 loss per share); adjusted EBITDA loss $6.4M.","Patient & Digital Solutions revenue $8.6M, up 39% YoY; cash $285.9M, no debt.","Withdrew 2023 revenue guidance due to MolDX Billing Article revisions in March and May 2023.","Delayed submission of ~$8.9M in AlloSure Kidney Medicare tests from Q1 to Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-23-000094","json":"https://secwatch.observer/filing/0001217234-23-000094.json","markdown":"https://secwatch.observer/filing/0001217234-23-000094.md","text":"https://secwatch.observer/filing/0001217234-23-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000094/0001217234-23-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000094/cdna-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:55:42.411515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"429abe1c28c357b483b8409a723b17ff3dfdd11c","claim":"CareDx, Inc. reported the first quarter ended March 31, 2023 results: revenue $77.3 million, net income net loss of $23.7 million, EPS basic and diluted net loss per share of $0.44.","evidence_excerpt":"test results for AlloMap® and AlloSure® of approximately 49,900 tests, growing year-over-year by 17%, and exceeding year-over-year market growth of 10%. • Reported revenue of $77.3 million, a decrease of 3% year-over year. This excludes approximately $8.9 million in revenue associated with approximately 3,200 AlloSure Kidney Medicare tests that the Company did not","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000094/0001217234-23-000094-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$77.3 million"},{"label":"Net income","value":"net loss of $23.7 million"},{"label":"EPS","value":"basic and diluted net loss per share of $0.44"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}